As the race to send humans back to the moon heats up, China has been fine-tuning its plans. On Saturday – the day after the US company SpaceX successfully launched its largest and most powerful Starship – the China Manned Space Agency unveiled further details about its plans to integrate its crewed and uncrewed lunar landing programmes into a single mission. The purpose was “to fully leverage the ...
As the race to send humans back to the moon heats up, China has been fine-tuning its plans. On Saturday – the day after the US company SpaceX successfully launched its largest and most powerful Starship – the China Manned Space Agency unveiled further details about its plans to integrate its crewed and uncrewed lunar landing programmes into a single mission. The purpose was “to fully leverage the technical foundations and practical experience accumulated over decades through crewed space programmes and the Chang’e lunar exploration missions ”, agency spokesman Zhang Jingbo told a press conference at the Jiuquan Satellite Launch Centre. Advertisement Zhou Yaqiang, a senior engineer at the China Manned Space Agency, told reporters that the process of “combining experiences and expertise” from the various missions was “progressing smoothly”. When asked about the US-China moon race, Zhou reiterated the official Chinese position, saying that the country was committed to the peaceful use of space. Advertisement “We carry out the project of crewed lunar exploration under the established plan. We are not competing with other countries in space. Our crewed lunar programme is also not subject to interference from any factors,” he said. “When Chinese astronauts land on the moon in the future, this will be a great feat for all of humanity. It will help increase our understanding of space.”
WEST PALM BEACH, FL / ACCESS Newswire / May 24, 2026 / Management Celebrates Friday Trading Momentum of 7.96% and States That Growing Worldwide Awareness of ELEKTROS Represents a Paradigm Shift for the Company's Expanding Global Shareholder Base. ELEKTROS States That Growing Global Awareness Surrounding the Company Represents an Exciting Milestone for Shareholders and Supporters Worldwide. ELEKTRO...
WEST PALM BEACH, FL / ACCESS Newswire / May 24, 2026 / Management Celebrates Friday Trading Momentum of 7.96% and States That Growing Worldwide Awareness of ELEKTROS Represents a Paradigm Shift for the Company's Expanding Global Shareholder Base. ELEKTROS States That Growing Global Awareness Surrounding the Company Represents an Exciting Milestone for Shareholders and Supporters Worldwide. ELEKTROS continues focusing on hard rock lithium exploration and development opportunities in Sierra Leone, Africa, positioning the Company within one of the world's most strategically important supply chains supporting electric vehicles, renewable energy storage, and industrial electrification. The importance of lithium to the future of transportation and clean energy has been repeatedly highlighted by industry leaders worldwide. Elon Musk, CEO of Tesla, previously stated: "It is definitely true that the fundamental enabling technology for electric cars is lithium-ion as a cell chemistry technology. In the absence of that, I don't think it's possible to make an electric car that is competitive with a gasoline car." In addition, Musk has publicly emphasized the importance of expanding charging infrastructure and improving charging efficiency to support mass EV adoption globally. In parallel with its lithium initiatives, ELEKTROS holds United States Patent No. 12,522,100 B1 related to advanced electric vehicle charging technology designed to significantly reduce charging times and improve charging efficiency for EV users globally. The Company believes that fast-charging infrastructure may become one of the defining components of the next generation EV ecosystem as consumers increasingly demand reduced charging times, improved convenience, and enhanced vehicle usability. ELEKTROS further announced that on May 5, 2026, the Company delivered a cease-and-desist notice regarding activities involving a major global automotive manufacturer whose identity the Company has elected not to pub...
AbbVie (ABBV +0.56%) and Pfizer (PFE 0.19%) are two top healthcare stocks, and they're investments that can generate a ton of dividend income for your portfolio. AbbVie, which yields 3.2%, has been a dividend growth beast for decades and has been doing a good job of growing its business even after its top-selling drug Humira lost patent protection. It has proven to be a good long-term dividend inv...
AbbVie (ABBV +0.56%) and Pfizer (PFE 0.19%) are two top healthcare stocks, and they're investments that can generate a ton of dividend income for your portfolio. AbbVie, which yields 3.2%, has been a dividend growth beast for decades and has been doing a good job of growing its business even after its top-selling drug Humira lost patent protection. It has proven to be a good long-term dividend investment to hang on to. Pfizer offers a higher yield of 6.7%, but it's a bit riskier, given that it's still in the midst of trying to get back to growth and is facing some daunting patent cliffs in the near future. For investors, the pressing issue is whether the business is on the right track and if its dividend is indeed safe. Below, I'll look at which of these dividend stocks is the better option for income investors right now. Is Pfizer's dividend really safe? The biggest question for income investors when analyzing these two stocks may come down to the safety of Pfizer's payout. Regardless of the yield, if the dividend is in danger, what percentage Pfizer pays today may be meaningless, and thus, AbbVie's stock would be the better option by default. The problem, however, is that you can't just look at Pfizer's payout ratio, which is over 100%, because there has been so much noise in its earnings in recent quarters. The company has gone through restructuring, and one-time expenses such as impairment charges have weighed on its bottom line. Expand NYSE : PFE Pfizer Today's Change ( -0.19 %) $ -0.05 Current Price $ 25.90 Key Data Points Market Cap $148B Day's Range $ 25.76 - $ 26.15 52wk Range $ 23.06 - $ 28.75 Volume 22.3M Avg Vol 37.3M Gross Margin 65.16 % Dividend Yield 6.64 % Its free cash flow has totaled $9.5 billion over the past four quarters, which is a bit lower than the $9.8 billion the company has paid in dividends during that time frame. But with Pfizer trimming costs and looking to become leaner, that shortfall may not be terribly concerning, at least not yet,...
Starlux, EVA Air retain Skytrax five-star status Two of Taiwan’s international carriers, Starlux Airlines Co (星宇航空) and EVA Airways Corp (長榮航空), have retained the five-star airline rating awarded by international airline review organization Skytrax. Starlux was awarded the distinction for a second consecutive year, while EVA Air received it for the 11th straight year, Skytrax said in statements re...
Starlux, EVA Air retain Skytrax five-star status Two of Taiwan’s international carriers, Starlux Airlines Co (星宇航空) and EVA Airways Corp (長榮航空), have retained the five-star airline rating awarded by international airline review organization Skytrax. Starlux was awarded the distinction for a second consecutive year, while EVA Air received it for the 11th straight year, Skytrax said in statements released yesterday and on Thursday last week, respectively. The five-star rating is considered one of the airline industry's highest honors and is awarded following professional audits of airline product and frontline service standards, Skytrax said. The ratings are based on in-depth assessments using unified global quality standards rather than customer review scores